Upfront Autologous Stem Cell Transplantation (ASCT) vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation with K Maintenance in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Phase 2 Non-Inferiority Cardamon Study
Social Science Research Network（2022）
关键词
multiple myeloma,carfilzomib-cyclophosphamide-dexamethasone,transplant-eligible,non-inferiority
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要